U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Factor X Inactivation

MedGen UID:
1375228
•Concept ID:
C4329970
•
Disease or Syndrome

Definition

Presence of inactivating antibodies to factor X in the blood. [from NCI]

Professional guidelines

PubMed

An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.
Joseph BC, Miyazawa BY, Esmon CT, Cohen MJ, von Drygalski A, Mosnier LO
Blood Adv 2022 Feb 8;6(3):959-969. doi: 10.1182/bloodadvances.2021005257. PMID: 34861695Free PMC Article
Clinical management of protein C deficiency.
Pescatore SL
Expert Opin Pharmacother 2001 Mar;2(3):431-9. doi: 10.1517/14656566.2.3.431. PMID: 11336597
Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Edwards CA, Piet MP, Chin S, Horowitz B
Vox Sang 1987;52(1-2):53-9. doi: 10.1111/j.1423-0410.1987.tb02989.x. PMID: 3111089

Recent clinical studies

Etiology

The role of tissue factor pathway inhibitor 2 in the coagulation and fibrinolysis system.
Kobayashi H, Matsubara S, Imanaka S
J Obstet Gynaecol Res 2023 Jul;49(7):1677-1683. Epub 2023 Apr 25 doi: 10.1111/jog.15660. PMID: 37186495
Protein arginine deiminase 4 inactivates tissue factor pathway inhibitor-alpha by enzymatic modification of functional arginine residues.
Thomassen MCLGD, Bouwens BRC, Wichapong K, Suylen DP, Bouwman FG, Hackeng TM, Koenen RR
J Thromb Haemost 2023 May;21(5):1214-1226. Epub 2023 Jan 28 doi: 10.1016/j.jtha.2023.01.017. PMID: 36716968
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center.
Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH
Clin Appl Thromb Hemost 2019 Jan-Dec;25:1076029619896619. doi: 10.1177/1076029619896619. PMID: 31876159Free PMC Article
The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica 2003 Jun;88(6):EREP02. PMID: 12826528
Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.
Crowther MA, Berry LR, Monagle PT, Chan AK
Br J Haematol 2002 Jan;116(1):178-86. doi: 10.1046/j.1365-2141.2002.03233.x. PMID: 11841415

Diagnosis

Protein arginine deiminase 4 inactivates tissue factor pathway inhibitor-alpha by enzymatic modification of functional arginine residues.
Thomassen MCLGD, Bouwens BRC, Wichapong K, Suylen DP, Bouwman FG, Hackeng TM, Koenen RR
J Thromb Haemost 2023 May;21(5):1214-1226. Epub 2023 Jan 28 doi: 10.1016/j.jtha.2023.01.017. PMID: 36716968
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG
J Clin Invest 2022 Jul 1;132(13) doi: 10.1172/JCI145099. PMID: 35579943Free PMC Article
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K, Nogami K
Arterioscler Thromb Vasc Biol 2020 May;40(5):1148-1154. Epub 2020 Apr 2 doi: 10.1161/ATVBAHA.120.312919. PMID: 32237902
Regulation of coagulation by protein S.
Castoldi E, Hackeng TM
Curr Opin Hematol 2008 Sep;15(5):529-36. doi: 10.1097/MOH.0b013e328309ec97. PMID: 18695379
Clinical management of protein C deficiency.
Pescatore SL
Expert Opin Pharmacother 2001 Mar;2(3):431-9. doi: 10.1517/14656566.2.3.431. PMID: 11336597

Therapy

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center.
Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH
Clin Appl Thromb Hemost 2019 Jan-Dec;25:1076029619896619. doi: 10.1177/1076029619896619. PMID: 31876159Free PMC Article
Andexanet Alfa: First Global Approval.
Heo YA
Drugs 2018 Jul;78(10):1049-1055. doi: 10.1007/s40265-018-0940-4. PMID: 29926311Free PMC Article
Activation, activity and inactivation of factor VIII in factor VIII products.
Orfeo T, Elsman R, Gissel M, Mann KG, Butenas S
Haemophilia 2016 May;22(3):462-73. Epub 2016 Jan 29 doi: 10.1111/hae.12872. PMID: 26822998
rFVIIai in Acute Coronary Syndromes.
Sorensen BB, Hedner U, Erhardtsen E
Semin Vasc Med 2003 May;3(2):199-204. doi: 10.1055/s-2003-40678. PMID: 15199483
Anticoagulation: a surgical perspective.
Perry MO
Am J Surg 1988 Feb;155(2):268-76. doi: 10.1016/s0002-9610(88)80712-8. PMID: 3277474

Prognosis

Deciphering the coagulation profile through the dynamics of thrombin activity.
de Laat-Kremers RMW, Yan Q, Ninivaggi M, de Maat M, de Laat B
Sci Rep 2020 Jul 27;10(1):12544. doi: 10.1038/s41598-020-69415-y. PMID: 32719370Free PMC Article
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center.
Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH
Clin Appl Thromb Hemost 2019 Jan-Dec;25:1076029619896619. doi: 10.1177/1076029619896619. PMID: 31876159Free PMC Article
Demeanor of rivaroxaban in activated/inactivated FXa.
Seki K, Mizuno Y, Sakashita T, Nakano S, Tanno J, Okazaki Y, Muramatsu T, Nishimura S, Senbonmatsu T
J Pharmacol Sci 2017 Mar;133(3):156-161. Epub 2017 Feb 24 doi: 10.1016/j.jphs.2017.02.010. PMID: 28314697
Modeling of human factor Va inactivation by activated protein C.
Bravo MC, Orfeo T, Mann KG, Everse SJ
BMC Syst Biol 2012 May 20;6:45. doi: 10.1186/1752-0509-6-45. PMID: 22607732Free PMC Article
Specificity of alpha 2-macroglobulin covalent cross-linking for the active domain of proteinases.
Pizzo SV, Rajagopalan S, Roche PA, Fuchs HE, Feldman SR, Gonias SL
Biol Chem Hoppe Seyler 1986 Nov;367(11):1177-82. doi: 10.1515/bchm3.1986.367.2.1177. PMID: 2434119

Clinical prediction guides

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center.
Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH
Clin Appl Thromb Hemost 2019 Jan-Dec;25:1076029619896619. doi: 10.1177/1076029619896619. PMID: 31876159Free PMC Article
Mass Spectrometry Reveals a Multifaceted Role of Glycosaminoglycan Chains in Factor Xa Inactivation by Antithrombin.
Minsky BB, Abzalimov RR, Niu C, Zhao Y, Kirsch Z, Dubin PL, Savinov SN, Kaltashov IA
Biochemistry 2018 Aug 14;57(32):4880-4890. Epub 2018 Jul 25 doi: 10.1021/acs.biochem.8b00199. PMID: 29999301Free PMC Article
Latent antithrombin and its detection, formation and turnover in the circulation.
Mushunje A, Evans G, Brennan SO, Carrell RW, Zhou A
J Thromb Haemost 2004 Dec;2(12):2170-7. doi: 10.1111/j.1538-7836.2004.01047.x. PMID: 15613023
rFVIIai in Acute Coronary Syndromes.
Sorensen BB, Hedner U, Erhardtsen E
Semin Vasc Med 2003 May;3(2):199-204. doi: 10.1055/s-2003-40678. PMID: 15199483
Thrombin receptor activating peptide does not stimulate platelet procoagulant activity.
Goodwin CA, Wheeler-Jones CP, Kakkar VV, Deadman JJ, Authi KS, Scully MF
Biochem Biophys Res Commun 1994 Jul 15;202(1):321-7. doi: 10.1006/bbrc.1994.1930. PMID: 8037727

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...